FrancophonIA/ELRC3.0 huggingface dataset:
English: Administration of pazopanib to patients with mild or moderate hepatic impairment should be undertaken with caution and close monitoring.
Croatian: U bolesnika s blagim ili umjerenim oštećenjem jetre pazopanib se treba primjenjivati s oprezom i uz pomno praćenje.
English: The maximally tolerated pazopanib dose (MTD) in patients with moderate hepatic impairment (defined as an elevation of bilirubin >1.5 x to 3 x ULN regardless of the ALT values) was 200 mg once daily.
Croatian: Najveća podnošljiva doza pazopaniba u bolesnika s umjerenim oštećenjem jetrene funkcije (definirano kao povećanje bilirubina >1,5 x do 3 x GGN neovisno o vrijednostima ALT-a) je 200 mg jednom dnevno.
English: - increase in the number of red blood cells - sudden shortness of breath, especially when accompanied with sharp pain in the chest and /or rapid breathing (pulmonary embolism) - severe bleeding in the digestive system (such as stomach, oesophagus or intestine), or the kidneys, vagina and brain - heart rhythm disturbance (QT prolongation) - hole (perforation) in stomach or intestine - abnormal passages forming between parts of the intestine (fistula) - heavy or irregular menstrual periods - sudden sharp increase in blood pressure (hypertensive crisis) - inflammation of the pancreas (pancreatitis) - liver inflamed, not working well or damaged - yellowing of the skin or whites of the eyes (jaundice) - inflammation of the lining of the abdominal cavity (peritonitis) - runny nose - rashes which may be itchy or inflamed (flat or raised spots or blisters) - frequent bowel movements - increased sensitivity of the skin to sunlight - decreased feeling or sensitivity, especially in the skin
Croatian: Oni mogu naštetiti organima poput mozga i bubrega. - povećanje broja crvenih krvnih stanica - iznenadan nedostatak zraka, osobito u kombinaciji s oštrom boli u prsnom košu i/ili ubrzanim disanjem (plućna embolija) - jako krvarenje u probavnom sustavu (poput želuca, jednjaka ili crijeva) ili bubrezima, rodnici i mozgu - poremećaj srčanog ritma (produljenje QT intervala) - rupa (perforacija) u želucu ili crijevima - abnormalni prolazi koji se stvaraju između dijelova crijeva (fistule) - jake ili neredovite menstruacije - iznenadno naglo povećanje krvnog tlaka (hipertenzivna kriza) - upala gušterače (pankreatitis) - upala jetre, nedovoljan rad jetre ili oštećenje jetre - pojava žutila kože ili bjeloočnica (žutica) - upala ovojnice trbušne šupljine (peritonitis) - curenje iz nosa - osip koji može svrbjeti ili biti upaljen (ravne ili izdignute mrlje ili mjehuri) - učestale stolice - povećana osjetljivost kože na sunčevu svjetlost - smanjen osjet, osobito kože
English: Don't breast-feed while taking Votrient.
Croatian: Nemojte dojiti za vrijeme uzimanja lijeka Votrient.
English: Signs and symptoms may include: - severe stomach pain - nausea and/or vomiting - fever - development of a hole (perforation) in the stomach, intestine or bowel from which bloody or foul smelling pus is released
Croatian: Znakovi i simptomi mogu uključivati: - jaku bol u želucu - mučninu i/ili povraćanje - vrućicu - razvoj rupe (proboja) u želucu, crijevima ili zdjelici iz koje se oslobađa krvavi ili smrdljivi gnoj Odmah potražite liječničku pomoć u slučaju pojave bilo kojega od navedenih simptoma.
English: Each film-coated tablet contains 200 mg pazopanib (as hydrochloride).
Croatian: Jedna filmom obložena tableta sadrži 200 mg pazopaniba (u obliku pazopanibklorida).
English: Baseline laboratory measurement of thyroid function is recommended and patients with hypothyroidism should be treated as per standard medical practice prior to the start of pazopanib treatment.
Croatian: Prije započinjanja terapije pazopanibom preporučuje se mjerenje početnih vrijednosti funkcije štitnjače, a bolesnici s hipotireozom trebaju biti pod uobičajenom terapijom.
English: Administration of 1500 mg lapatinib (a substrate for and weak inhibitor of CYP3A4 and P-gp and a potent inhibitor of BCRP) with 800 mg pazopanib resulted in an approximately 50% to 60% increase in mean pazopanib AUC(0-24) and Cmax compared to administration of 800 mg pazopanib alone.
Croatian: U usporedbi sa samostalnom primjenom 800 mg pazopaniba, istovremena primjena 1500 mg lapatiniba (supstrat i slabi inhibitor CYP3A4 i P-gp-a i potentni inhibitor za BCRP) i 800 mg pazopaniba rezultirala je s povećanjem od oko 50% do 60% srednjih vrijednosti AUC(0-24) i Cmax za pazopanib.
English: Pazopanib is not recommended in patients with severe hepatic impairment (total bilirubin >3 x ULN regardless of the ALT value) (see sections 4.2 and 5.2).
Croatian: Pazopanib se ne preporučuje bolesnicima s teškim oštećenjem jetre (definirano kao ukupni bilirubin >3 x GGN neovisno o vrijednosti ALT-a) (vidjeti dijelove 4.2 i 5.2).
English: - If you do become pregnant during treatment with Votrient, tell your doctor.
Croatian: - Recite svom liječniku ako zatrudnite tijekom terapije lijekom Votrient.
English: The median steady-state Cmax and AUC(0-24) values after administration of 200 mg pazopanib once daily in patients with severe hepatic impairment were approximately 18% and 15%, of the corresponding median values after administration of 800 mg once daily in patients with normal hepatic function.
Croatian: Medijan vrijednosti Cmax odnosno AUC(0-24) u stanju dinamičke ravnoteže nakon primjene 200 mg pazopaniba jednom dnevno u bolesnika s teškim oštećenjem funkcije jetre iznosio je oko 18% odnosno 15% odgovarajućih medijana vrijednosti nakon primjene 800 mg pazopaniba jednom dnevno u bolesnika s normalnom funkcijom jetre.
English: What Votrient looks like and contents of the pack Votrient 200 mg film-coated tablets are capsule-shaped, pink with “GS JT” marked on one side.
Croatian: Votrient 200 mg filmom obložene tablete su oblika kapsule, roze s oznakom „GS JT“ na jednoj strani.
English: 800 mg pazopanib once daily is the recommended dose in patients with mild abnormalities in serum liver tests (defined either as normal bilirubin and any degree of alanine aminotransferase (ALT) elevation or as an elevation of bilirubin (>35% direct) up to 1.5 x upper limit of normal (ULN) regardless of the ALT value).
Croatian: Preporučena doza pazopaniba je 800 mg jednom dnevno, u bolesnika s blagim poremećajima serumskih jetrenih testova (definirani ili kao normalni bilirubin i bilo koji stupanj povišenja alanin aminotransferaze (ALT) ili kao povišenje bilirubina (>35% direktnog) do 1,5 x gornje granice normale (GGN) neovisno o vrijednosti ALT-a).
English: 30 film-coated tablets 90 film-coated tablets
Croatian: Filmom obložena tableta 30 filmom obloženih tableta 90 filmom obloženih tableta
English: Liver problems
Croatian: Problemi s jetrom
English: All patients should have liver function tests to determine whether they have hepatic impairment before starting and during pazopanib therapy (see section 4.4).
Croatian: Prije započinjanja i tijekom liječenja pazopanibom u svih bolesnika treba provoditi testove jetrene funkcije kako bi se utvrdilo imaju li oštećenje jetre (vidjeti dio 4.4).
English: Inhibition of P-gp and/or BCRP by lapatinib likely contributed to the increased exposure to pazopanib.
Croatian: Povećanoj izloženosti pazopanibu vjerojatno je doprinijela inhibicija P-gp-a i/ili BCRP-a lapatinibom.
English: - if you have thyroid problems.
Croatian: - ako imate problema sa štitnjačom.
English: Each Votrient 200 mg film-coated tablet contains 200 mg pazopanib.
Croatian: Jedna Votrient 200 mg filmom obložena tableta sadrži 200 mg pazopaniba.
English: 200 mg OD
Croatian: 200 mg JD
English: In clinical studies with pazopanib, events of GI perforation or fistula have occurred (see section 4.8).
Croatian: U kliničkim ispitivanjima pazopaniba zabilježeni su slučajevi GI perforacije ili fistula (vidjeti dio 4.8).
English: Concomitant treatment with inducers of CYP3A4 should be avoided due to risk of decreased exposure to pazopanib (see section 4.5).
Croatian: Zbog rizika od smanjene izloženosti pazopanibu treba se izbjegavati istovremena terapija lijekovima koji su induktori CYP3A4 (vidjeti dio 4.5).
English: Pazopanib resulted in an increase of approximately 30% in the mean AUC and Cmax of midazolam (CYP3A4 probe substrate) and increases of 33% to 64% in the ratio of dextrometrophan to dextrophan concentrations in the urine after oral administration of dextromethorphan (CYP2D6 probe substrate).
Croatian: Nakon peroralne primjene dekstrometorfana (probni supstrat CYP2D6), pazopanib je rezultirao povećanjem prosječne vrijednosti od oko 30% za AUC i Cmax za midazolam (probni supstrat CYP3A4) i povećanje od 33% do 64% odnosa koncentracija dekstrometorfana i dekstrofana u urinu.
English: Capsule-shaped, white, film-coated tablet with GS UHL debossed on one side.
Croatian: Bijela, filmom obložena tableta oblika kapsule s utisnutom oznakom „GS UHL“ na jednoj strani.
English: Pazopanib should be discontinued in patients with wound dehiscence.
Croatian: Liječenje pazopanibom se treba prekinuti u bolesnika s dehiscencijom rane.
English: 150 mg/m resulted in an approximately 20% increase in systemic exposure to SN-38.
Croatian: Istodobna primjena pazopaniba 400 mg jednom dnevno s cetuksimabom 250 mg/m i irinotekanom 150 mg/m rezultirala je povećanjem sistemske izloženosti za SN-38 od približno 20%.
English: Each Votrient 400 mg film-coated tablet contains 400 mg pazopanib.
Croatian: Jedna Votrient 400 mg filmom obložena tableta sadrži 400 mg pazopaniba.
English: x axis; Months, y axis; Proportion Progression Free, Pazopanib --- (N = 155) Median 11.1 months; Placebo -------- (N = 78) Median 2.8 months; Hazard Ratio = 0.40, 95% CI (0.27, 0.60), P <0.0000001
Croatian: os x; mjeseci, os y; udio bez progresije, pazopanib --- (N = 155) medijan 11,1 mjeseci; placebo -------(N = 78) medijan 2,8 mjeseci; omjer hazarda = 0,40; 95% CI (0,27; 0,60); P <0,0000001
English: PRES/RPLS has been reported in association with pazopanib.
Croatian: Postoje prijave slučajeva PRES/RPLS koji su povezani s terapijom pazopanibom.
English: 30 film-coated tablets 60 film-coated tablets
Croatian: Filmom obložena tableta 30 filmom obloženih tableta 60 filmom obloženih tableta
English: Uncommon Oropharyngeal pain 3 (<1%) Bronchial haemorrhage 2 (<1%) Rhinorrhoea
Croatian: eritematozni osip poremećaji kože makularni osip pruritički osip vezikularni osip generalizirani svrbež 2 (<1%) generalizirani osip papularni osip plantarni eritem 1 (<1%)
English: See Table 1 for dose modification guidance for patients with baseline values of total bilirubin 1.5 x ULN and AST and ALT 2 x ULN:
Croatian: Vidjeti tablicu 1 za smjernice za prilagodbu doze u bolesnika s početnim vrijednostima ukupnog bilirubina 1,5 x GGN te početnim vrijednostima AST-a i ALT-a 2 x GGN: Tablica 1 Prilagodba doze u slučaju hepatotoksičnosti uzrokovane primjenom lijeka Vrijednosti jetrenih testova
English: x axis; Months, y axis; Proportion Progression Free, Pazopanib --- (N = 290) Median 9.2 months; Placebo ------- (N = 145) Median 4.2 months; Hazard Ratio = 0.46, 95% CI (0.34, 0.62), P <0.0000001
Croatian: os x; mjeseci, os y; udio bez progresije, pazopanib --- (N = 290) medijan 9,2 mjeseca; placebo -------(N = 145) medijan 4,2 mjeseca; omjer hazarda = 0,46; 95% CI (0,34; 0,62); P <0,0000001
English: x axis; Months, y axis; Proportion Progression Free, Pazopanib --- (N = 135) Median 7.4 months; Placebo -------- (N = 67) Median 4.2 months; Hazard Ratio = 0.54, 95% CI (0.35, 0.84), P <0.001
Croatian: os x; mjeseci, os y; udio bez progresije, pazopanib --- (N = 135) medijan 7,4 mjeseca; placebo -------(N = 67) medijan 4,2 mjeseca; omjer hazarda = 0,54; 95% CI (0,35; 0,84), P <0,001
English: ILD, which can be fatal, has been reported in association with pazopanib (see section 4.8).
Croatian: Intersticijska bolest pluća, koja može imati smrtni ishod, prijavljena je u vezi s terapijom pazopanibom (vidjeti dio 4.8).
English: A reduced pazopanib dose of 200 mg once daily is recommended in patients with moderate hepatic impairment (defined as an elevation of bilirubin >1.5 to 3 x ULN regardless of the ALT value) (see section 5.2).
Croatian: Smanjena doza pazopaniba od 200 mg jednom dnevno se preporučuje u bolesnika s umjerenim oštećenjem jetre (definirano kao povišenje bilirubina >1,5 x do 3 x GGN neovisno o vrijednosti ALT-a) (vidjeti dio 5.2).
English: Pregnancy
Croatian: Leiomiosarkom
English: Very common Decreased appetite Hypoalbuminemia f
Croatian: Poremećaji metabolizma i prehrane vrlo često smanjen apetit hipoalbuminemija f često dehidracija manje često hipomagnezijemija 1 (<1%) 0
English: A reduced pazopanib dose of 200 mg once daily is recommended in patients with moderate hepatic impairment (elevation of bilirubin >1.5 to 3 x ULN regardless of the ALT value) (see sections 4.2 and 5.2).
Croatian: Smanjena doza pazopaniba od 200 mg jednom dnevno se preporučuje u bolesnika s umjerenim oštećenjem jetre (definirano kao povišenje bilirubina >1,5 x do 3 x GGN neovisno o vrijednosti ALT-a) (vidjeti dijelove 4.2 i 5.2).
English: The median steady-state Cmax and AUC(0-24) values after administration of 200 mg pazopanib once daily in patients with moderate hepatic impairment were approximately 44% and 39%, of the corresponding median values after administration of 800 mg once daily in patients with normal hepatic function, respectively (see Table 7).
Croatian: Nakon primjene 200 mg pazopaniba jednom dnevno u bolesnika s umjerenim poremećajem jetrene funkcije medijan vrijednosti Cmax odnosno AUC(0-24) u stanju dinamičke ravnoteže je približno 44% odnosno 39% odgovarajućih medijana vrijednosti nakon primjene 800 mg pazopaniba jednom dnevno u bolesnika s normalnom funkcijom jetre (vidjeti tablicu 7).
English: Cerebrovascular accident
Croatian: Moždani udar
English: The median steady-state pazopanib Cmax and AUC(0-24) in patients with mild abnormalities in hepatic parameters (defined as either normal bilirubin and any degree of ALT elevation or as an elevation of bilirubin up to 1.5 x ULN regardless of the ALT value) after administration of 800 mg once daily are similar to the median in patients with normal hepatic function (see Table 7).
Croatian: Nakon primjene 800 mg pazopaniba jednom dnevno medijani Cmax i AUC(0-24) u stanju dinamičke ravnoteže za pazopanib u bolesnika s blagim poremećajem jetrenih parametara (definirani kao ili normalni bilirubin i bilo koji stupanj porasta vrijednosti ALT-a ili kao povećanje bilirubina do 1,5 x gornje granice normale (GGN) neovisno o vrijednosti ALT-a) bile su slične medijanu u bolesnika s normalnom funkcijom jetre (vidjeti tablicu 7).
English: In clinical studies with pazopanib, events of QT prolongation and torsade de pointes have occurred (see section 4.8).
Croatian: U kliničkim ispitivanjima pazopaniba zabilježeni su slučajevi produljenja QT intervala i torsade de pointes (vidjeti dio 4.8).
English: Synovial sarcoma subgroups
Croatian: Podgrupe sinovijalnog sarkoma
English: Myocardial dysfunction occurred in 13% (47/362) of subjects in the pazopanib arm compared to 11% (42/369) of subjects in the sunitinib arm. Congestive heart failure was observed in 0.5% of subjects in each treatment arm. Congestive heart failure was reported in 3 out of 240 subjects (1%) in the Phase III VEG110727 STS study.
Croatian: Disfunkcija miokarda se pojavila u 13% (47/362) ispitanika u skupini koja je primala pazopanib u usporedbi s 11% (42/369) ispitanika u skupini koja je primala sunitinib.
English: - Use a reliable method of contraception while you're taking Votrient, and at least for 2 weeks after, to prevent pregnancy.
Croatian: - Kako biste spriječili trudnoću za vrijeme i 2 tjedna nakon uzimanja lijeka Votrient, koristite sigurne metode kontracepcije.
English: Decreased corpora lutea, increased cysts and ovarian atrophy have also been noted in rodents.
Croatian: U glodavaca je zabilježeno i smanjenje žutih tijela, povećanje broja cisti i atrofija ovarija.
English: No dose adjustment is required in patients with creatinine clearance above 30 ml/min.
Croatian: U bolesnika s klirensom kreatinina iznad 30 ml/min nije potrebna prilagodba doze.
English: BOTTLE LABEL - 200 mg film-coated tablets
Croatian: NALJEPNICA BOCE - 200 mg filmom obložene tablete
English: The clinical status of the patient and the adverse event profile of pazopanib should be borne in mind when considering the patient's ability to perform tasks that require judgement, motor or cognitive skills.
Croatian: Pri razmatranju bolesnikove sposobnosti provođenja aktivnosti koje zahtijevaju mogućnost rasuđivanja te motoričke i kognitivne vještine, treba imati na umu klinički status bolesnika i profil nuspojava pazopaniba.
English: Check with your doctor if you think this applies to you.
Croatian: Ako smatrate da se to odnosi na Vas, provjerite to sa svojim liječnikom.
English: Mild, indirect (unconjugated) hyperbilirubinaemia may occur in patients with Gilbert's syndrome.
Croatian: U bolesnika s Gilbertovim sindromom može doći do razvoja blage indirektne (nekonjugirane) hiperbilirubinemije.
English: BOTTLE LABEL - 400 mg film-coated tablets
Croatian: NALJEPNICA BOCE - 400 mg filmom obložene tablete
English: In clinical studies with pazopanib, events of hypothyroidism have occurred (see section 4.8).
Croatian: U kliničkim ispitivanjima pazopaniba zabilježeni su slučajevi hipotireoze (vidjeti dio 4.8).
English: Figure 1 Kaplan-Meier curve for progression-free survival by independent assessment for the overall population (treatment-naïve and cytokine pre-treated populations) (VEG105192)
Croatian: Slika 1 Kaplan-Meierova krivulja preživljenja bez progresije za sveukupnu populaciju prema neovisnoj procjeni (populacija bez ranije terapije i populacija liječena citokinima) (VEG105192)
English: If you get any side effects, talk to your doctor or pharmacist.
Croatian: Ako uzimate bilo koji od ovih lijekova, recite to svom liječniku ili ljekarniku.
English: (CYP3A4 and CYP2C8 substrate) once weekly resulted in a mean increase of 26% and 31% in paclitaxel AUC and Cmax, respectively.
Croatian: Istovremena primjena 800 mg pazopaniba jednom dnevno i 80 mg/m paklitaksela (supstrat CYP3A4 i CYP2C8) jednom tjedno rezultirala je prosječnim povećanjem AUC za paklitaksel od 26% i Cmax za paklitaksel od 31%.
English: If no medically acceptable alternative to a strong CYP34A inhibitor is available, the dose of pazopanib should be reduced to 400 mg daily during concomitant administration.
Croatian: Treba izbjegavati istodobnu primjenu pazopaniba i jakih CYP3A4 inhibitora (vidjeti dio 4.4).Ukoliko nije dostupna medicinski prihvatljiva alternativa jakom CYP3A4 inhibitoru, dozu pazopaniba treba smanjiti na 400 mg dnevno tijekom razdoblja istodobne primjene.
English: Uncommon Somnolence
Croatian: Psihijatrijski poremećaji često nesanica
English: Decreased appetite and anorexia f Cardiac dysfunction, left ventricular dysfunction, cardiac failure and restrictive cardiomyopathy g
Croatian: Disfunkcija srca, disfunkcija lijevog ventrikula, zatajenje srca i restriktivna kardiomiopatija g Venski tromboembolijski događaj, duboka venska tromboza, plućna embolija i tromboza
English: Rare
Croatian: Teško
English: Votrient 400 mg film-coated tablets
Croatian: Votrient 400 mg filmom obložene tablete
English: Votrient 200 mg film-coated tablets Votrient 400 mg film-coated tablets
Croatian: Votrient 200 mg filmom obložene tablete Votrient 400 mg filmom obložene tablete
English: Votrient 200 mg film-coated tablets
Croatian: Votrient 200 mg filmom obložene tablete
English: 800 mg pazopanib once daily is the recommended dose in patients with mild abnormalities of serum liver tests (see section 4.2).
Croatian: Preporučena doza pazopaniba u bolesnika s blagim poremećajem jetrenih testova je 800 mg jednom dnevno (vidjeti dio 4.2).
English: Figure 2 Kaplan-Meier curve for progression-free survival by independent assessment for the treatment-naïve population (VEG105192)
Croatian: Slika 2 Kaplan-Meierova krivulja preživljenja bez progresije za populaciju bez ranije terapije prema neovisnoj procjeni (VEG105192)
English: Uncommon Thrombotic microangiopathy (including thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome)
Croatian: Poremećaji krvnog i limfnog sustava često trombocitopenija neutropenija leukopenija manje često policitemija rijetko trombotička mikroangiopatija (uključujući trombotičku trombocitopeničnu purpuru i hemolitički uremični sindrom)†
English: 800 mg pazopanib once daily is the recommended dose in patients with mild abnormalities in serum liver tests (either normal bilirubin and any degree of ALT elevation or elevation of bilirubin up to 1.5 x ULN regardless of the ALT value).
Croatian: Preporučena doza pazopaniba je 800 mg jednom dnevno u bolesnika s blagim poremećajem serumskih jetrenih testova (definirani ili kao normalni bilirubin i bilo koji stupanj porasta vrijednosti alanin aminotransferaze (ALT) ili kao povišenje bilirubina do 1,5 x gornje granice normale (GGN) neovisno o vrijednosti ALT-a).
English: Uncommon Bradycardia Myocardial infarction 5 (<1%) Cardiac dysfunctionf Myocardial ischaemia 3 (<1%)
Croatian: Srčani poremećaji često disfunkcija srca g disfunkcija lijeve klijetke bradikardija manje često infarkt miokarda 1 (<1%) 0
English: Capsule-shaped, pink, film-coated tablet with GS JT debossed on one side.
Croatian: Roza, filmom obložena tableta oblika kapsule s utisnutom oznakom „GS JT“ na jednoj strani.
English: Votrient 200 mg film-coated tablets Votrient 400 mg film-coated tablets pazopanib
Croatian: Votrient 200 mg filmom obložene tablete Votrient 400 mg filmom obložene tablete pazopanib
English: Titanium dioxide (E171)
Croatian: Ovojnica tablete hipromeloza makrogol 400 polisorbat 80 titanijev dioksid (E171)
English: Venous thromboembolic event, deep vein thrombosis, pulmonary embolism and thrombosis
Croatian: Duboka venska tromboza (DVT) i plućna embolija
English: Hepatic effects
Croatian: Učinci na jetru
English: Concomitant use of pazopanib and simvastatin increases the risk of ALT elevations (see section 4.5) and should be undertaken with caution and close monitoring.
Croatian: Potreban je oprez i pomno praćenje pri istodobnoj uporabi pazopaniba i simvastatina uslijed povišenog rizika porasta vrijednosti ALT-a (vidjeti dio 4.5).
English: Figure 3 Kaplan-Meier Curve for progression-free survival by independent assessment for the cytokine pre-treated population (VEG105192)
Croatian: Slika 3 Kaplan-Meierova krivulja preživljenja bez progresije prema neovisnoj procjeni za populaciju koja je ranije primala terapiju citokinima (VEG105192)
English: Votrient 200 mg film-coated tablets pazopanib
Croatian: Votrient 200 mg filmom obložene tablete pazopanib
English: The following terms have been combined: a Abdominal pain, abdominal pain upper and gastrointestinal pain b Oedema, oedema peripheral and eyelid oedema c
Croatian: Sljedeći su pojmovi združeni: a Bol u abdomenu, bol u gornjem dijelu abdomena i bol u donjem dijelu abdomena b
English: You will be checked for thyroid hormone levels while you are taking Votrient.
Croatian: Za vrijeme uzimanja lijeka Votrient kontrolirat će se razina hormona štitnjače.
English: Mild
Croatian: Umjereno
English: Votrient 400 mg film-coated tablets pazopanib
Croatian: Votrient 400 mg filmom obložene tablete pazopanib
English: Blood clots
Croatian: Krvni ugrušci
English: Uncommon Jaundice Drug induced liver injury
Croatian: nepoznato nepoznato nepoznato manje često infekcija gingive infektivni peritonitis
English: Cardiac dysfunction g
Croatian: Blago oštećenje funkcije jetre
English: Common Abdominal distension 16 (4%) Dry mouth
Croatian: Poremećaji oka često zamućenje vida 15 (4%) 0
English: Rectal haemorrhage 2 (<1%) Enterocutaneous fistula 1 (<1%) Gastric haemorrhage 1 (<1%) Melaena
Croatian: Poremećaji oka često zamućenje vida manje često odvajanje mrežnice† 1 (<1%) razdor mrežnice† promjena boje trepavica 4 (<1)
English: Enterocutaneous fistula
Croatian: Prijavljivanje nuspojava
English: Dysgeusia, ageusia and hypogeusia d White cell count decreased, neutrophil count decreased and leukocyte count decreased e
Croatian: Smanjeni broj bijelih krvnih stanica, smanjeni broj neutrofila i smanjeni broj leukocita e Smanjenje apetita i anoreksija f